Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | DAO | P14920 | 1/20 | 0.38 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.38 |
| ▸ | ATAD2 | Q6PL18 | 3/20 | 0.37 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.36 |
| ▸ | NSD2 | O96028 | 2/20 | 0.36 |
| ▸ | SETD2 | Q9BYW2 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 7/20 | 0.36 |
| ▸ | EIF4A3 | P38919 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3418416 | 0.76 | APEX1 (0.47) | HPGDHSD17B10MEN1USP2ALDH1A1 | |
| SCHEMBL3626110 | 0.70 | HPGD (0.53) | HPGDHSD17B10MEN1USP2ALDH1A1 | |
| SCHEMBL1144741 | 0.67 | HPGD (0.60) | HPGDHSD17B10MEN1USP2ALDH1A1 | |
| SCHEMBL3238955 | 0.67 | MEN1 (0.49) | HPGDHSD17B10MEN1USP2ALDH1A1 | |
| SCHEMBL17136028 | 0.67 | HSD17B10 (0.64) | HPGDHSD17B10MEN1USP2ALDH1A1 | |
| SCHEMBL1653805 | 0.66 | NPC1 (0.53) | HPGDHSD17B10MEN1ALDH1A1KMT2A | |
| SCHEMBL11035155 | 0.65 | HSD17B10 (0.62) | HPGDHSD17B10MEN1USP2ALDH1A1 | |
| SCHEMBL2004648 | 0.65 | KDM4E (0.63) | HPGDHSD17B10MEN1USP2ALDH1A1 | |
| SCHEMBL17865525 | 0.65 | F7 (0.41) | MEN1ALDH1A1KMT2AHRH4 | |
| SCHEMBL3061718 | 0.65 | WDR5 (0.50) | ALDH1A1APEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3037412-B1 | INDOLE AMIDE COMPOUND AS INHIBITOR OF NECROSIS | LG CHEMICAL LTD (KR) | 2020-09-30 | — | — | EP | claimed |
| US-9868731-B2 | Indole amide compound as inhibitor of necrosis | LG CHEM, LTD. (KR) | 2018-01-16 | — | — | US | claimed |
| US-20160194313-A1 | INDOLE AMIDE COMPOUND AS INHIBITOR OF NECROSIS | LG LIFE SCIENCES LTD. (KR) | 2016-07-07 | — | — | US | claimed |
| EP-3037412-A1 | INDOLE AMIDE COMPOUND AS INHIBITOR OF NECROSIS | LG Life Sciences Ltd. (KR) | 2016-06-29 | — | — | EP | claimed |
| EP-3037412-B1 | INDOLE AMIDE COMPOUND AS INHIBITOR OF NECROSIS | LG CHEMICAL LTD (KR) | 2020-09-30 | — | — | EP | disclosed |
| US-9868731-B2 | Indole amide compound as inhibitor of necrosis | LG CHEM, LTD. (KR) | 2018-01-16 | — | — | US | disclosed |
| US-20160194313-A1 | INDOLE AMIDE COMPOUND AS INHIBITOR OF NECROSIS | LG LIFE SCIENCES LTD. (KR) | 2016-07-07 | — | — | US | disclosed |
| EP-3037412-A1 | INDOLE AMIDE COMPOUND AS INHIBITOR OF NECROSIS | LG Life Sciences Ltd. (KR) | 2016-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160194313-A1 | INDOLE AMIDE COMPOUND AS INHIBITOR OF NECROSIS | IDO1, IDO2, TNF | HPGD 181/4885HSD17B10 1348/4885MEN1 1819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.